Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 26, Issue 7, 2016, Pages 1803-1808

  Simov, Vladimir ^a   Deshmukh, Sujal V ^c   Dinsmore, Christopher J ^b   Elwood, Fiona ^a   Fernandez, Rafael B ^a   Garcia, Yudith ^a   Gibeau, Craig ^a   Gunaydin, Hakan ^a   Jung, Joon ^d   Katz, Jason D ^a   Kraybill, Brian ^e   Lapointe, Blair ^a   Patel, Sangita B ^a   Siu, Tony ^a   Su, Hua ^a   Young, Jonathan R ^f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Forma Therapeutics   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d Ironwood Pharmaceuticals   (United States)

^e ALCON RESEARCH LTD   (United States)

^f CELGENE CORPORATION   (United States)

Author keywords

JAK1 kinase inhibitor; Janus Kinase; Structure based design

Indexed keywords

BENZIMIDAZOLE; JANUS KINASE 1; JANUS KINASE INHIBITOR; PYRIDONE DERIVATIVE; RIBOSE; RUXOLITINIB; TOFACITINIB; BENZIMIDAZOLE DERIVATIVE; JAK1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; HYDROGEN BOND; IC50; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR MODEL; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

BENZIMIDAZOLES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; JANUS KINASE 1; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84979072426     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2016.02.035     Document Type: Article

References (29)

1. 1 Schindler, C., Levy, D.E., Decker, T., J. Biol. Chem., 282, 2007, 20059.
2. 2(a) O'Shea, J.J., Immunity, 7, 1997, 1.
3. 2(b) Pesu, M., Laurence, A., Kishore, N., Zwillich, S.H., Chan, G., O'Shea, J.J., Immunol. Rev., 223, 2008, 132.
4. 2(c) Ghoreschi, K., Laurence, A., O'Shea, J.J., Immunol. Rev., 228, 2009, 273.
5. 3(a) Tofacitinib for RA:Zerbini, C.A., Lomonte, A.B., Expert Rev. Clin. Immunol., 8, 2012, 319.
6. 3(b) Ruxolitinib for RA:Mesa, R.A., Yasothan, U., Kirkpatrick, P., Nat. Rev. Drug Disc., 11, 2012, 103.
7. 3(c) Ruxolitinib for myelofibrosis:Vaddi, K., Sarlis, N.J., Gupta, V., Expert Opin. Pharmacother., 13, 2012, 2397.
8. 4(a) Riese, R.J., Krishnaswami, S., Kremer, J., Best Pract. Res. Clin. Rheumatol., 24, 2010, 513.
9. 4(b) Verstovsek, S., Kantarijian, H., Mesa, R.A., Pardanani, A.D., Cortes-Franco, J., Thomas, D.A., Estrov, Z., Fridman, J.-S., Bradley, E.C., Erickson-Viitanen, S., Vaddi, K., Levi, R., Tefferi, A., N. Engl. J. Med., 363, 2010, 1552.
10. 4(c) Laurence, A., Pesu, M., Silvennoinen, O., O'Shea, J.J., Open Rheumatol. J., 6, 2012, 232.
11. 5 Compounds were tested in two cell-based assays for their ability to inhibit cytokine induced signaling, including (a) IL-6 stimulation related to JAK1/2-pSTAT3 pathway signaling and (b) EPO stimulation related to JAK2-pSTAT5 pathway signaling. In general, we have observed good correlation between the enzymatic JAK2/JAK1 ratio and the cell EPO/IL-6 ratio. See the Supporting information for more details.
12. 6(a) Brubaker, J.; Close, J.; Siu, T.; Smith, G. F.; Torres, L.; Woo, H. C.; Young, J.; Wei, Z.; Shi, F. WO 2013/041042, A1.
13. 6(b) Brubaker, J.; Childers, M. L.; Christopher, M.; Close, J.; Katz, J. D.; Jung, J.; Peterson, S.; Siliphaivanh, P.; Siu, T.; Smith, G. F.; Torres, L. E.; Woo, H. C.; Young, J. R.; Zhang, H. WO 2013/043962, A1.
14. 6(c) Zhang, H.; Siliphaivanh, P.; Siu, T.; Torres, L.; Brubaker, J.; Nagayoshi, M.; Martinez, M.; Close, J.; Childers, M.; MacCoss, R.; Young, J. R.; Dinsmore, C. J.; Jones, P.; Li, C.; Jung, J.; Pickford, F.; Deshmukh, S. V. Abstracts of Papers, 248th ACS National Meeting & Exposition, San Francisco, CA, United States, 2014; MEDI-372.
15. 7(a) Prior to our work, pyridone benzimidazoles had been described in the literature as tyrosine kinase inhibitors having anti-cancer activity. See: Wittman, M. D.; Balasubramanian, N.; Velaparthi, U.; Zimmermann, K.; Saulnier, M. G.; Liu, P.; Sang, X.; Frennesson, D.; Stoffan, K. M.; Tarrant, J. G. WO 2002/079192, A1.
16. 7(b) Velaparthi, U., Wittman, M., Liu, P., Carboni, M.J., Lee, F.Y., Attar, R., Balimane, P., Clarke, W., Sinz, M.W., Hurlburt, W., Patel, K., Lorell, D., Kim, S., Gottardis, M., Greer, A., Li, A., Saulnier, M., Yang, Z., Zimmermann, K., Trainor, G., Vyas, D., J. Med. Chem., 51, 2008, 5897.
17. 8(a) Ultimately, the goal was to achieve EPO/IL-6 pathway selectivity of 15-fold or higher in the cell-based pathway reporter gene assays in order to differentiate our compounds from the currently marketed pan-selective JAK inhibitors. For a discussion on previously reported strategies to displace or engage a conserved water molecule in medicinal chemistry, see:Stahl, M., Kuhn, B., Bissantz, C., J. Med. Chem. (Perspective), 53, 2010, 5061.
18. 8(b) Dunitz, D.J., Science, 264, 1994, 670.
19. 9 For an example exploring the P-loop hypothesis toward JAK1 selectivity, see:Friedman, M., Frank, K.E., Aguirre, An., Argiriadi, M.A., Davis, H., Edmunds, J.J., George, D.M., George, S.J., Goedken, E., Fiamengo, B., Hyland, D., Li, B., Murtaza, A., Morytko, M., Somal, G., Stewart, K., Tarcsa, E., Van Epps, S., Voss, J., Wang, L., Woller, K., Wishart, N., Bioorg. Med. Chem. Lett., 25, 2015, 4399.
20. 10 Calculations were performed at the B3LYP/6-31+G(d) level of theory by using the G09 program in implicit solvent model (iefpcm).
21. 11 Upon completion of this work, a similar observation was made and published by Genentech in their effort to identify a JAK1-selective inhibitor. See:Zak, M., Hurley, A.C., Ward, S.I., Bergeron, P., Barrett, K., Balazs, M., Blair, W.S., Bull, R., Chakravarty, P., Chang, C., Crackett, P., Deshmukh, G., DeVoss, J., Dragovich, P.S., Eigenbrot, C., Ellwood, C., Gaines, S., Ghilardi, N., Gibbons, P., Gradl, S., Gribling, P., Hamman, C., Harstad, E., Hewitt, P., Johnson, A., Johnson, T., Kenny, J.R., Koehler, M.F.T., Bir Kohli, P., Labadie, S., Lee, W.P., Liao, J., Liimatta, M., Mendonca, R., Narukulla, R., Pulk, R., Reeve, A., Savage, S., Shia, S., Steffek, M., Ubhayakar, S., van Abbema, A., Aligas, I., Avitabile-Woo, B., Xiao, Y., Yang, J., Kulagowski, J.J., J. Med. Chem., 56, 2013, 4764.
22. 12 Functional selectivity for IL-6 signaling versus EPO signaling was performed by measuring the inhibition of EPO driven proliferation of human CD34+ hematopoietic stem cells and IL-6 driven secretion of MCP1 from human PBMCs.
23. 13 IL-7 signaling in human and/or rat whole blood was measured by stimulating with IL-7 and measuring pSTAT5 in the CD3+ CD4+ cell subset by flow cytometry.
24. 14 Tested at Invitrogen using SelectScreen™ Kinase Profiling (www.thermofisher.com).
25. 15(a) Whartenby, K.A., Calabresi, P.A., McCadden, E., Nguyen, B., Kardian, d., Thianhong, W., Mosse, C., Pardoll, D.M., Small, D., Proc. Natl. Acad. Sci. U.S.A., 102, 2005, 16741.
26. 15(b) Karsunky, H., Merad, M., Cozzio, A., Weissman, I.L., Manz, M.G., J. Exp. Med., 198, 2003, 305.
27. 16(a) The only measured non-JAK kinase that showed <100-fold IC50activity relative to JAK1 was NUAK1. NUAK1 is a member of the AMPK (AMP-activated protein kinase) family of protein kinases that are activated by the LKB1 tumor suppressor kinase and plays an important role in regulating key biological processes, such as tumorigenesis, senescence, cell adhesion and neuronal polarity. There is some evidence suggesting that NUAK1 participates in induction of tumor survival, however, for the most part, its detailed biological functions remain unclear. See:Hou, X., Liu, J.E., Liu, W., Liu, C.Y., Liu, Z.Y., Sun, Z.Y., Oncogene, 30, 2011, 2933.
28. 16(b) Banerjee, S., Buhrlage, S.J., Huang, H.T., Deng, X., Zhou, W., Wang, J., Traynor, R., Prescott, A.R., Alessi, D.R., Gray, N.S., Biochem. J., 457, 2014, 215.
29. 17 Rodgers, J. D.; Robinson, D. J.; Arvanitis, A. G.; Maduskuie, T. P. Jr.; Shepard, S.; Storace, L.; Wang, H.; Rafalski, M.; Jalluri, R. K.; Combs, A. P.; Crawley, M. L. WO 2005/105814, A1.